# Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

> **NCT05681195** · PHASE2 · RECRUITING · sponsor: **Baptist Health South Florida** · enrollment: 15 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma
- Relapsed Cancer
- Refractory Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Zanubrutinib
- **PROCEDURE:** Autologous Stem Cell Transplant (ASCT)
- **RADIATION:** Whole Brain Radiation Therapy (WBRT)

## Key facts

- **NCT ID:** NCT05681195
- **Lead sponsor:** Baptist Health South Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-25
- **Primary completion:** 2028-02
- **Final completion:** 2033-02
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05681195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05681195, "Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05681195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*